L ong before he found himself in the middle of a multibillion-dollar takeover battle for a coveted new weight-loss drug, Whit ...

LLY's Mounjaro and Zepbound deliver accelerated weight loss rates compared to NVO's Wegovy, which perhaps explains the former ...

Berkshire Hathaway's diversification, culture, and investment philosophy should still make it a great long-term buy, but ...

Middle-class Indians trying to lose weight are embracing drugs such as Mounjaro, which is also used to treat diabetes in a ...

By Rishabh Jaiswal, Sabrina Valle and Maggie Fick NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion ...

Eli Lilly and Company (NYSE:LLY) develops medicines for diabetes, obesity, cancer, autoimmune disorders, and neurological conditions.

NEW YORK/LONDON (Reuters) -A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker ...

Learn more about whether BioMarin Pharmaceutical Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Experts say the deal to lower the cost of the drugs is ambitious, but left some with more questions than answers.

A viral video circulated online in November 2025 that purported to show the United States Secretary of the Department of ...

The deal announced on Thursday, covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government ...